Next, we analyzed four different RNA-seq datasets from ICI-treated patient cohorts with MM of various genotypes (combined cohorts of anti-CTLA-4, anti-PD-1 or anti-CTLA-4 and anti-PD-1 therapy; Van Allen et al., Liu et al., Riaz et al. and Gide et al.; exact patient numbers are provided in the Methods)16–19. This evidence concerns the gene CTLA4 and Miyoshi myopathy.